Effect of the α2 -receptor agonists medetomidine, detomidine, xylazine, and romifidine on the ketamine metabolism in equines assessed with enantioselective capillary electrophoresis.

This research analyzed how four different α2-receptor agonists—medetomidine, detomidine, xylazine, and romifidine—affect the metabolism of ketamine in horses. The findings revealed that these drugs alter the formation of ketamine byproducts norketamine, 6-hydroxynorketamine (6HNK), and 5,6-dehydronorketamine (DHNK), with medetomidine being the strongest inhibitor.

Objective of Research

• The primary objective of this study was to understand the impact of four different α2-receptor agonists—medetomidine, detomidine, xylazine, and romifidine—on the metabolism of ketamine in equines.
• Furthermore, the research aimed at exploring the inhibition characteristics for the N-demethylation of ketamine to norketamine and the formation of the ketamine metabolites norketamine, 6-hydroxynorketamine (6HNK), and 5,6-dehydronorketamine (DHNK).

Method

• The study involved analysing samples with enantioselective capillary electrophoresis using highly sulfated γ-cyclodextrin as chiral selector.
• Equine liver microsomes were examined in the presence of the four α-receptor agonists.
• Both short and extended incubation periods of the reaction mixture were investigated to understand the effects of these α-receptor agonists on ketamine metabolism.

Findings

• The research concluded that all four α-receptor agonists—medetomidine, detomidine, xylazine, and romifidine—have an impact on the ketamine metabolism.
• Among the four, medetomidine showed the most potent inhibitory effect on ketamine metabolism, followed by detomidine.
• Xylazine and romifidine showed almost no effect on the ketamine N-demethylation in the inhibition studies with a short-incubation period of the reaction mixture. However, after prolonged incubation, inhibition with xylazine and romifidine was noticed.
• The formation of 6HNK and DHNK was affected by all the investigated α-receptor agonists. The levels of these metabolites were reduced with medetomidine as compared to cases without an α-receptor agonist. Interestingly, for detomidine, xylazine, and romifidine, an increase in the levels of these metabolites was observed.

Implication

• This study enhances the understanding of how different α2-receptor agonists impact the metabolism of ketamine in horses, which is crucial in veterinary medicine, especially during equine surgery.
• The findings can potentially impact decision-making in the choice of an α2-receptor agonist to use in combination with ketamine. This knowledge might help in managing recovery post anaesthesia in equines and reducing unforeseen complications.